Open an account

Syndax Pharmaceuticals

SNDX · NASDAQ

$13.25+$0.16 (+1.22%)TodayMarket closed ·
Prev close $13.09

About SNDX

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. The company is headquartered in New York City, New York and currently employs 298 full-time employees. The company went IPO on 2016-03-03. The company is focused on developing a pipeline of cancer therapies. Its product candidates include Revuforj and Niktimvo. The company is developing Revuforj, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant AML. The company is also exploring the use of Revuforj as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. The company is also developing Niktimvo, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.

Employees
298
Headquarters
New York City, New York
Listed
Mar 3, 2016
Sector
Health Care
Industry
Biotechnology
Website
syndax.com

SNDX key statistics

Market cap
1.18B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
2.19M
Volume
3.91M
Open price
$13.20
High today
$13.59
Low today
$12.97
52 Week high
$25.59
52 Week low
$12.80

Syndax Pharmaceuticals (SNDX) at a glance

Syndax Pharmaceuticals (SNDX) last traded at $13.25, with a market cap of 1.18B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $12.97 and $13.59. The current price is 2.2% above the day's low and 2.5% below its high.

Volume so far is 3.91M shares, above the average of 2.19M shares a day.

Over the past year Syndax Pharmaceuticals has ranged from $12.80 to $25.59, and now sits 4% of the way up that range.

Syndax Pharmaceuticals met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.55 per share against an estimate of -$0.4511.

The average analyst price target is $39.78, 200.2% above the current price, from 10 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 10 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 14 analystsAvg $39.78
Low
$26.26
Now
$13.25
High
$59.85

SNDX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 17.0% on average.

  1. Q3 FY24: reported -$0.98 per share against an estimate of -$1.14
  2. Q4 FY24: reported -$1.10 per share against an estimate of -$0.2337
  3. Q1 FY25: reported -$0.98 per share against an estimate of -$1.36
  4. Q2 FY25: reported -$0.83 per share against an estimate of -$1.04
  5. Q3 FY25: reported -$0.70 per share against an estimate of -$0.731
  6. Q4 FY25: reported -$0.78 per share against an estimate of -$0.5958
  7. Q1 FY26: reported -$0.48 per share against an estimate of -$0.5937
  8. Q2 FY26: reported -$0.55 per share against an estimate of -$0.4511

SNDX news

  • Press releaseBusiness Wire

    SNDX Investors with $100,000 in Losses Have Opportunity to Join Syndax Pharmaceuticals, Inc. Fraud Investigation with SBS Law

  • Press releasePRNewswire

    Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)

  • Vandana Singh

    Syndax Pharmaceuticals Suffers Pipeline Blow

  • Avi Kapoor

    Crude Oil Edges Higher; Citigroup Earnings Top Views

  • Avi Kapoor

    Syndax Pharmaceuticals, BioNTech, Seagate And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session

  • Press releaseGlobe Newswire

    Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update

  • Press releaseGlobe Newswire

    Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026

  • Press releaseGlobe Newswire

    Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Similar companies

Companies in the same industry as Syndax Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.